Diabetes

Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray.

The bill would reduce prices up to 75% based on anticipated 2020 levels, according to Senator Jeanne Shaheen, D-NH, the lead sponsor.

Under new guidance released by Internal Revenue Service and the Department of Treasury, high-deductible health plans (HDHPs) with health savings accounts can cover chronic care treatment before a patient meets their deductible.

Researchers are closing in on a sought after goal of a blood test that can detect posssible signs of Alzheimer disease and other forms of dementia; Planned Parenthood President Leana Wen, MD, has been ousted after 8 months; Abbott Laboratories is ramping up manufacturing capacity for its lower-cost continuing glucose monitor FreeStyle Libre.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

An exercise-focused intervention may be effective for improving mental health, work ability, and productivity outcomes while reducing metabolic syndrome severity for individuals at a high risk for cardiovascular and metabolic disease, according to researchers.

This week, the top managed care news included uncertainty surrounding the fate of the Affordable Care Act's individual mandate; a study finding Medicare beneficiaries may be paying more for some generics than brand-name drugs; the Trump administration proposing 5 new payment models to transform kidney disease care.

HHS has launched a summit to streamline and improve quality programs across the agency; more than 160 children with type 1 diabetes (T1D) appeared before a Senate committee to ask for more funding for the Special Diabetes Program; the CDC has confirmed 11 cases of a rare polio-like illness in 8 states.

Following an executive order from President Donald Trump, HHS announced the launch of Advancing American Kidney Health, an initiative to improve the health of the 37 million Americans living with kidney disease, by releasing 5 new payment models.

Physician, patient, and caregiver education is important to improve diabetes care, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.

Network analyses of patients with diabetes in Hawaii illustrate structures and links that health plans could leverage to strengthen quality improvement and disease management programs.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

The Triple Aim will be within reach when there is greater stakeholder engagement and systemic ownership. A good start is for more employers to provide more American workers with access to high-quality wellness programs that can impact chronic disease with population health strategies.

This week, we recap the top managed care news from the first half of 2019, including outcomes from some of the biggest diabetes trials, research into the annual Medicare wellness visit, and an experimental treatment in Parkinson disease.

With more than 30 million patients with diabetes and only 6000 endocrinologists, that primary care doctor is playing a crucial role in seeing diabetics, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.

Coverage of DECLARE, CARMELINA, and other studies that highlight the connection between diabetes and renal outcomes

The Los Angeles gathering of the Institute for Value-Based Medicine focused on the need to intervene early in the course of diabetes, so that patients can avoid long-term complications. Over the past decade, cardiovascular outcomes trials for glucose-lowering therapies have revealed unexpected benefits, offering new opportunities for cardiologists.

Here are the top 5 articles for the month of June.

Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous cardiovascular disease.

Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.

The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.

Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.

A Senate Committee has voted to require drug companies to justify steep drug price hikes to the federal government; Pfizer has added former FDA Commissioner Scott Gottlieb, MD, to its board of directors; the FDA warned consumers of potential cybersecurity risks associated with certain mini Medtronic insulin pumps.

Diabetes is a self-managed disease, which makes the role of diabetes education crucial in order for patients to succeed in managing their disease, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included a report finding slow progress in reducing low-value care; a study finding savings by accountable care organizations may be overstated; CMS proposing a rule to allow for electronic prior authorization in Part D drugs.

Collaboration between cardiologists and endocrinologists are necessary when caring with patients with diabetes who have had cardiovascular issues in the past, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.

Merck's Center for Observational and Real-World Evidence has spent several years gathering evidence on clinical inertia and is now working on solutions to overcome it at the point of care.

The FDA's approval of the glucagon-like peptide receptor agonist marks the first non-insulin drug approved for youth with type 2 diabetes since the approval of metformin for pediatric use in 2000.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.